Elanco director receives new stock unit awards

Scots-Knight Denise reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Scots-Knight Denise reported acquisition or exercise transactions in this Form 4 filing.

Elanco Animal Health director Denise Scots-Knight received equity compensation awards rather than buying shares on the market. She was granted 12,196 deferred stock units as a pro-rated annual equity award and 4,678 restricted stock units as an annual equity award to non-employee board members.

Following these grants, her directly held common stock and stock-based awards reported in the filing total 105,588 shares for one award category and 93,392 shares for the other. These awards were granted at no cash cost per unit, reflecting standard board compensation in stock-based form.

Insider Trade Summary

Grant/Award: 16,874 shares

Grant/Award 2 txns

Insider Scots-Knight Denise

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	4,678	$0.00	$0.00
Grant/Award	Common Stock	12,196	$0.00	$0.00

Holdings After Transaction: Common Stock — 105,588 shares (Direct)

Footnotes (2)

1. F1. Grant of deferred stock units as a pro-rated annual equity award to each of the non-employee members of the Issuer's Board of Directors.
2. F2. Grant of restricted stock units as an annual equity award to each of the non-employee members of the Issuer's Board of Directors.

Key Figures

Deferred stock units granted: 12,196 shares Restricted stock units granted: 4,678 shares Price per granted share: $0.0000 per share +3 more

6 metrics

Deferred stock units granted 12,196 shares Pro-rated annual equity award on May 21, 2026

Restricted stock units granted 4,678 shares Annual equity award on May 21, 2026

Price per granted share $0.0000 per share Both stock unit grants

Shares following DSU grant 105,588 shares Total shares following deferred stock unit grant

Shares following RSU grant 93,392 shares Total shares following restricted stock unit grant

Acquire transactions 2 transactions Form 4 summary for May 21, 2026 grants

Key Terms

deferred stock units, restricted stock units, non-employee members of the Issuer's Board of Directors, Grant, award, or other acquisition

4 terms

deferred stock units financial

"Grant of deferred stock units as a pro-rated annual equity award"

Deferred stock units are promises from a company to give an employee shares of stock at a future date, often after certain conditions are met or after leaving the company. They function like a form of delayed compensation, allowing employees to earn shares over time. For investors, they represent potential future ownership in the company, but do not provide immediate voting rights or dividends until the shares are actually received.

restricted stock units financial

"Grant of restricted stock units as an annual equity award"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

non-employee members of the Issuer's Board of Directors financial

"annual equity award to each of the non-employee members of the Issuer's Board of Directors"

Grant, award, or other acquisition regulatory

"transaction_code_description: Grant, award, or other acquisition"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Elanco (ELAN) director Denise Scots-Knight report on this Form 4?

She reported receiving two equity awards in Elanco common stock. The filing shows 12,196 deferred stock units and 4,678 restricted stock units granted as part of annual compensation for non-employee board members.

Were Denise Scots-Knight’s Elanco (ELAN) transactions open-market purchases or grants?

They were grants, not open-market purchases. Both transactions use code “A,” described as grants or awards, with a price per share of $0.0000, indicating stock-based compensation rather than shares bought for cash.

How many Elanco (ELAN) shares were granted to Denise Scots-Knight?

She was granted 12,196 deferred stock units and 4,678 restricted stock units of Elanco common stock. These represent stock-based compensation awards provided to non-employee members of the company’s Board of Directors.

What are the footnotes explaining Denise Scots-Knight’s Elanco (ELAN) Form 4 awards?

The footnotes state the 12,196 units are a pro-rated annual deferred stock unit award, and the 4,678 units are restricted stock units, both granted as equity awards to non-employee Elanco board members.

How many Elanco (ELAN) shares does Denise Scots-Knight hold after these grants?

After these grants, the filing shows 105,588 shares following the deferred stock unit grant and 93,392 shares following the restricted stock unit grant, reflecting her reported direct holdings in each award category.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/26/2026 - 04:47 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Scots-Knight Denise

(Last) (First) (Middle)

C/O ELANCO ANIMAL HEALTH INCORPORATED

450 ELANCO CIRCLE

(Street)

INDIANAPOLIS INDIANA 46221

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Elanco Animal Health Inc [ ELAN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/21/2026		A		4,678(1)	A	$0	93,392	D
Common Stock	05/21/2026		A		12,196(2)	A	$0	105,588	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Grant of deferred stock units as a pro-rated annual equity award to each of the non-employee members of the Issuer's Board of Directors.

2. Grant of restricted stock units as an annual equity award to each of the non-employee members of the Issuer's Board of Directors.

	/s/ Amy C. Seidel, as Attorney-in-Fact for Denise K. Scots-Knight	05/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)